News That Matters

Tag: against

DNA vaccine shows promising, long-term results against Ebola virus

DNA vaccine shows promising, long-term results against Ebola virus

Health
Oct. 10 (UPI) -- A synthetic DNA vaccine is showing immediate and long-term promising results against the Ebola virus in preclinical animal research. Scientists at The Wistar Institute Vaccine and Immunotherapy Centers designed optimized synthetic DNA vaccine candidates that target a virus surface protein called glycoprotein. The findings were published Wednesday in the Journal of Infectious Diseases. The Zaire Ebolavirus infection causes a severe hemorrhagic fever with a 50 percent fatality rate. Ebola, which is transmitted to people from wild animals and spreads in the human population through human-to-human transmission, first appeared in 1976 in what is now, Nzara, South Sudan, and in Yambuku, Democratic Republic of Congo. "Synthetic non-viral based DNA technology allows for rapid vac...
Injured Joe Ledley and Tom Lockyer out of Wales squad against Spain and Republic

Injured Joe Ledley and Tom Lockyer out of Wales squad against Spain and Republic

Sports
Friendly: Wales v SpainVenue: Cardiff City Stadium Date: Thursday, 11 October Kick-off: 19:45 BSTCoverage: Live on BBC Radio 5 live, Radio Wales and Radio Cymru, the BBC Sport website and BBC Sport app, plus live text commentary.Wales manager Ryan Giggs has made two changes to a 25-man squad for the friendly against Spain on 11 October and the Nations League match with Republic of Ireland five days later. Joe Ledley and Tom Lockyer have withdrawn injured, with Jazz Richards and George Thomas replacing them.Leicester City forward Thomas, 21, could win his first competitive cap after impressing for the Under-21s. Wales play Spain at the Principality Stadium and the Republic in Dublin.Derby Coun...
Vaccine, drug combo promising against HPV-related cancers

Vaccine, drug combo promising against HPV-related cancers

Health
Sept. 27 (UPI) -- Combining a tumor-specific vaccine with an immune checkpoint inhibitor shrank tumors in one third of patients with incurable cancer related to HPV, according to a phase II clinical trial. Participants were injected with the vaccine ISA101, which targets important peptides from a cancer-promoting HPV16 genotype of human papillomavirus, and nivolumab, a drug that blocks activation of PD-1 on T cells. The findings were published Thursday in the Journal of the Medical Association Oncology. "That encouraging response rate is about twice the rate produced by PD1 checkpoint inhibitors in previous clinical trials, so these results will lead to larger, randomized clinical trials of this combination," principal investigator Dr. Bonnie Glisson, a professor of thoracic/head and neck...
The case for and against gender quotas

The case for and against gender quotas

Finance
Why does the gender wage gap still exist? In Europe, gender quotas are old news. In 2003, Norway became the first country in the world to institute a gender quota for boards of directors, requiring listed companies to add female members to make up at least 40% of overall board representation. Other countries followed suit, including Belgium, France and Italy. But in the United States, companies are loathe to institute gender and diversity requirements for membership, even as representation numbers continue to lag. Margarethe Wiersema, professor of management at the University of California-Irvine, says the reason behind the hesitancy is very simple: Americans don't like being told what to do. "Europe is so far ahead of us. It's like we're in the Dark Ages on this," s...
An analyst warns investors against falling for a widely-held assumption about rising tech stocks

An analyst warns investors against falling for a widely-held assumption about rising tech stocks

Finance
Come Monday, the tech-heavy Nasdaq will try to kick-off its second positive week in a row. But it's poised to do so without small cap tech and Chinese internet companies. According to veteran market watcher Nicholas Colas, much of Wall Street is mistakenly assuming that the technology sector's big surge is broad-based. "It's largely a large cap phenomenon," the DataTrek Research co-founder said Friday on CNBC's "Trading Nation." The Nasdaq is now up almost 25 percent over the past 52-weeks, while the broader S&P 500 is up 16 percent in that same p...